September 6 (SeeNews) - Bulgarian pharmaceuticals maker Sopharma [BUL:SFA] said that its consolidated net profit rose to 43.4 million levs ($22.01 million/22.2 million euro) in the first half of 2022 from 32.2 million levs a year earlier.
Growth was driven by higher revenue as well as a decrease in financial costs, the company said in an interim financial statement last week.
Total revenue climbed to 810.5 million levs in the six months through June from 771.2 million levs in the same period of 2021. The company booked solid product sales growth in the states of the Eurasian Economic Union, Serbia and Moldova.
Operating expenses in the period under review increased to 764.5 million levs from 731.8 million levs a year earlier. Cost of goods sold, which form the majority of operating expenses, widened to 585.4 million levs from 557.9 million levs.
Shares in Sopharma closed 1.31% lower at 4.52 levs on the Bulgarian Stock Exchange on Monday.
(1 euro = 1.95583 levs)